Abstract: The present disclosure relates to nanoparticles and methods for polynucleotide transfection.

Abstract: The present disclosure relates to nanoparticles and methods for polynucleotide transfection.

Abstract: The present disclosure relates to nanoparticles and methods for polynucleotide transfection.

Abstract: A respiratory syncytial virus (RSV) vaccine comprising a recombinant fusion protein antigen. In one embodiment, the recombinant fusion protein antigen comprises a phosphoprotein (P) moiety, wherein the P moiety is a polypeptide that shares at least 90% identity to the polypeptide represented by SEQ ID NO 2 or SEQ ID NO 4; and a flagellin moiety, wherein the flagellin moiety is a polypeptide that shares at least 90% identity to the polypeptide represented by SEQ ID NO 8; whereby the P moiety and flagellin moiety are covalently coupled so as to form a linear polypeptide.

Abstract: A respiratory syncytial virus (RSV) vaccine comprising a recombinant fusion protein antigen. In one embodiment, the recombinant fusion protein antigen comprises a phosphoprotein (P) moiety, wherein the P moiety is a polypeptide that shares at least 90% identity to the polypeptide represented by SEQ ID NO 2 or SEQ ID NO 4; and a flagellin moiety, wherein the flagellin moiety is a polypeptide that shares at least 90% identity to the polypeptide represented by SEQ ID NO 8; whereby the P moiety and flagellin moiety are covalently coupled so as to form a linear polypeptide.

Abstract: The present invention provides a vaccine composition for dental caries caused by S. mutans infection, where the vaccine composition comprises an antigen derived from a surface protein PAc of S. mutans and an adjuvant derived from flagellin. The present invention further provides methods for preparing the vaccine composition. The present invention also provides methods for preventing or curing dental caries caused by S. mutans by administrating to a subject the vaccine composition.

Abstract: The present invention provides a vaccine composition for dental caries caused by S. mutans infection, where the vaccine composition comprises an antigen derived from a surface protein PAc of S. mutans and an adjuvant derived from flagellin. The present invention further provides methods for preparing the vaccine composition. The present invention also provides methods for preventing or curing dental caries caused by S. mutans by administrating to a subject the vaccine composition.

Abstract: The present invention provides an optimized recombinant flagellin protein and preparation and use thereof. The protein is with a deletion in the hypervariable region, said hypervariable region is the region from 180 to 400 amino acid of the flagellin protein, and the proteins include FliC?190-278, FliC?220-320 or FliC?180-400. The method of preparing said protein, comprising introducing a deletion into the hypervariable region of the flagellin protein. First constructed the flagellin protein recombinant plasmid, and then used it as template to construct the flagellin deletion cloning, and expressed and purified. The present invention also provides the use of the recombinant flagellin protein as adjuvant. The recombinant flagellin protein in present invention decreases the potential risks it may have, and decreases its antigenicity and immunogenicity and the inflammatory response induced by it, through deleting its main areas of immunogenicity and antigen activity.

Abstract: The present invention provides an optimized recombinant flagellin protein and preparation and use thereof. The protein is with a deletion in the hypervariable region, said hypervariable region is the region from 180 to 400 amino acid of the flagellin protein, and the proteins include FliC?190-278, FliC?220-320 or FliC?180-400. The method of preparing said protein, comprising introducing a deletion into the hypervariable region of the flagellin protein. First constructed the flagellin protein recombinant plasmid, and then used it as template to construct the flagellin deletion cloning, and expressed and purified. The present invention also provides the use of the recombinant flagellin protein as adjuvant. The recombinant flagellin protein in present invention decreases the potential risks it may have, and decreases its antigenicity and immunogenicity and the inflammatory response induced by it, through deleting its main areas of immunogenicity and antigen activity.